Publications by authors named "Eleonora Gelli"
Article Synopsis
- - The FDA has approved a combination treatment of hypomethylating agents (HMA) with venetoclax (VEN) for elderly AML patients or those unable to undergo intense chemotherapy, but there's a risk of fungal infections requiring prophylactic posaconazole (PCZ).
- - There's a known drug interaction between VEN and PCZ, but the impact on venetoclax serum levels when these drugs are taken together remains unclear.
- - An analysis of plasma samples from 11 elderly AML patients found significant variability in venetoclax levels during treatment, highlighting the necessity for monitoring drug levels to ensure effective dosing.
Article Synopsis
- - Acute leukemia of ambiguous lineage (ALAL) is a rare and poorly understood type of leukemia with no established treatment guidelines due to its variability and lack of clinical trials.
- - A study of 10 ALAL cases revealed a high frequency of myeloid-gene mutations, particularly RUNX1 mutations, which are linked to an undifferentiated phenotype and lineage ambiguity.
- - The findings suggest that ALAL, particularly those with undifferentiated characteristics, may be genetically more similar to acute myeloid leukemia than acute lymphoblastic leukemia, indicating that treatment approaches might need to focus on AML-based therapies.
The dysregulation of the JAK/STAT pathway drives the pathogenesis of myelofibrosis (MF). Recently, several JAK inhibitors (JAKis) have been developed for treating MF. Select mutations (MTs) have been associated with impaired outcomes and are currently incorporated in molecularly annotated prognostic models.
View Article and Find Full Text PDF